Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 + TOMO vs S-1 + IMRT for locally advanced pancreatic cancer
ChiCTR-IPR-16009949Phase 4Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tegafur in pancreatic cancer (PC) (2 arms), sponsored by Xinhua Hospital. Primary endpoints: Overall response rate (ORR) and Disease control rate (DCR). Planned start Jan 2017; status: not yet recruiting.
02
Drugs
tegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR-IPR-16009949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009949.